Safer Canine Distemper Virus Vaccine

Description

This technology is a much safer, cutting-edge vaccine for canine distemper virus (CDV) that overcomes the potential pathogenicity found in current live CDV vaccines. CDV is a very contagious virus that can cause severe disease in young dogs and is found worldwide. Unfortunately, the mortality rate of canine distemper is about 50% in dogs and 80% in puppies.

While traditional CDV vaccines rely on live attenuated pathogens, our approach creates a vaccine that offers the same protective benefits with enhanced safety, by reducing the risk of vaccine reversion to virulent viral form. This innovation makes our vaccine a much safer choice for dogs of all ages and much more appealing to dog owners.

This unique CDV vaccine platform offers genetic stability, tunable strain attenuation, and antigen flexibility. Those features ensure consistent effectiveness over time but also allow adaptability for emerging strains. This vaccine platform could also potentially prevent virulence from paramyxoviruses of different strains.

Benefits

Much Safer: 100% of immunized animals survived infection with minimal symptoms. Peak viremia titers were slightly reduced compared to the unmodified parental strain.
Tunable Vaccine Platform: through targeted adjustments, researchers can enhance the vaccine’s ability to stimulate a robust immune response while minimizing side effects
Reduces Virus Replication: by targeting the replication of the canine distemper virus, this vaccine effectively mitigates the spread and severity of the disease among dogs.
Versatile Application: this vaccine can target other pathogens from paramyxoviruses of different strains